# Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences

> **NCT03955640** · PHASE1 · TERMINATED · sponsor: **Thomas Jefferson University** · enrollment: 3 (actual)

## Conditions studied

- Metastatic Malignant Neoplasm in the Chest Wall
- Recurrent Breast Carcinoma

## Interventions

- **DRUG:** Olaparib
- **PROCEDURE:** Hyperthermia Treatment
- **OTHER:** Questionnaire Administration
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT03955640
- **Lead sponsor:** Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-20
- **Primary completion:** 2021-08-26
- **Final completion:** 2021-08-26
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** PI decided not to move forward because of low accrual
- **Last updated:** 2025-12-22

## Collaborators

- AstraZeneca

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03955640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03955640, "Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03955640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*